Anne Prener
Director/Board Member chez GALECTO, INC.
Fortune : - $ au 31/03/2024
Postes actifs de Anne Prener
Sociétés | Poste | Début | Fin |
---|---|---|---|
GALECTO, INC. | Director/Board Member | 08/01/2021 | - |
Independent Dir/Board Member | 08/01/2021 | - | |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Director/Board Member | 27/03/2020 | - |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director/Board Member | 01/07/2020 | - |
Chief Executive Officer | 01/07/2020 | - | |
President | 01/07/2020 | - | |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/09/2020 | - |
Historique de carrière de Anne Prener
Anciens postes connus de Anne Prener
Sociétés | Poste | Début | Fin |
---|---|---|---|
RUBIUS THERAPEUTICS | Director/Board Member | 17/12/2019 | 12/07/2022 |
Independent Dir/Board Member | 17/12/2019 | 12/07/2022 | |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 01/07/2017 | 01/07/2019 |
Chief Executive Officer | 01/07/2017 | 01/07/2019 | |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 01/08/2016 | 01/03/2019 |
BAXALTA INC | Corporate Officer/Principal | 01/10/2014 | 01/07/2016 |
Novo Nordisk (Private Equity)
Novo Nordisk (Private Equity) Investment ManagersFinance Novo Nordisk A/S (CO: NOVO.B; NYSE: NVO), a Danish healthcare company which manufactures and markets pharmaceutical products and services worldwide, invests through their corporate venture fund NNBF-Novo Nordisk Biotech Fund (NNBF). Based in Bagsværd near Copenhagen, NNBF is a business unit within Novo Nordisk A/S, responsible for the company's venture capital activities. Investments are made on the books of Novo Nordisk A/S out of internal financial resources. NNBF is managed as an evergreen fund. | Director/Board Member | 01/01/2010 | 01/10/2014 |
░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Anne Prener
University of Copenhagen | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Royaume-Uni | 5 |
Danemark | 4 |
Opérationnelle
Director/Board Member | 8 |
Chief Executive Officer | 4 |
Independent Dir/Board Member | 3 |
Sectorielle
Health Technology | 10 |
Finance | 4 |
Miscellaneous | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
KALEIDO BIOSCIENCES, INC. | Health Technology |
GALECTO, INC. | Health Technology |
Entreprise privées | 10 |
---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Syncona Ltd.
Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company was founded on August 14, 2012, and is headquartered in St. Peter Port, the United Kingdom. | Miscellaneous |
Baxalta, Inc.
Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Novo Nordisk (Private Equity)
Novo Nordisk (Private Equity) Investment ManagersFinance Novo Nordisk A/S (CO: NOVO.B; NYSE: NVO), a Danish healthcare company which manufactures and markets pharmaceutical products and services worldwide, invests through their corporate venture fund NNBF-Novo Nordisk Biotech Fund (NNBF). Based in Bagsværd near Copenhagen, NNBF is a business unit within Novo Nordisk A/S, responsible for the company's venture capital activities. Investments are made on the books of Novo Nordisk A/S out of internal financial resources. NNBF is managed as an evergreen fund. | Finance |
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Finance |
- Bourse
- Insiders
- Anne Prener
- Expérience